The Histologic Diagnosis of Adenocarcinoma in Situ and Related Lesions of the Cervix Uteri

Jaworski, Richard; Pacey, N.F.; Greenberg, Merle L.; Osborn, R A

doi:10.1097/00006254-198809000-00021

Cited by 18 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In two other series, nearly all patients with AIS had abnormal smears 15,41 ; however, smear diagnoses previous to the abnormal smear are not mentioned. In an AIS series in which smears previous to the diagnostic smear were tabulated, 16 of 36 were negative within 3 years preceding the diagnosis.…”

Section: Discussionmentioning

confidence: 91%

Papanicolaou Smear Sensitivity for Adenocarcinoma In Situ of the Cervix:A Study of 34 Cases

Lee¹,

Minter²,

Granter³

1997

Am J Clin Pathol

View full text Add to dashboard Cite

The sensitivity of cervical smears for adenocarcinoma in situ (AIS) is not known, nor is it known whether false-negative smears are due to sampling or to screening or interpretive errors. In 16 of 34 patients with AIS, 38 negative smears were reported 2 weeks to 7 years before biopsy. Thirty-one of these negative smears were rescreened, and 17 (55%) were retrospectively diagnosed as abnormal. The purpose of this study was to obtain an estimate of Pap smear sensitivity for AIS and to uncover difficulties in interpretation of smears that may have led to false-negative diagnoses. MATERIALS AND METHODS The surgical p a t h o l o g y files of Brigham andWomen's Hospital, Boston, were searched for case reports of AIS or AIS combined with squamous cervical intraepithelial neoplasia (CIN) with a complete cone biopsy, hysterectomy, or both for the years 1986 to 1995. All available smears diagnosed as negative before an initial biopsy confirming AIS were confirmed sampling errors. The sensitivity of cervical smears for AIS was 55% to 72%. Improved sampling of the endocervical canal offers cytologists the opportunity to diagnose AIS. This study demonstrates that this opportunity may not be fully exploited. Small "endometrioid" AIS cells and AIS cells resembling reactive endocervical cells may be mistaken for benign cells, thus decreasing sensitivity.

show abstract

Section: Discussionmentioning

confidence: 91%

Papanicolaou Smear Sensitivity for Adenocarcinoma In Situ of the Cervix:A Study of 34 Cases

Lee¹,

Minter²,

Granter³

1997

Am J Clin Pathol

View full text Add to dashboard Cite

show abstract

“…Proliferative activity and expression of genes encoding cell cycle-regulating proteins in ACISs are similar to that of invasive ACs [31,32]. Besides characteristic morphologic features, such as crowded and hyperchromatic enlarged nuclei [25], the expression of CEA (carcinoembryonic antigen), p53 accumulation, and detection of proliferative activity by Ki-67 expression are used to distinguish ACISs/ASCISs from benign glandular proliferations [8]. ACISs/ASCISs have a similar epidemiologic profile relative to their invasive counterparts, with an average appearance 10 years earlier.…”

Section: Discussionmentioning

confidence: 99%

“…AC in situ (ACIS) of the cervix is a well-characterized and increasingly recognized pathologic entity, and some histologic subtypes are thought to be precursors of invasive ACs [3,4,7,9,23,25,51]. The fact that the high-risk HPV types 16 and 18 are already detectable in ACISs underlines the close relationship of ACISs to ACs.…”

Section: Introductionmentioning

confidence: 99%

Differences in HPV 16- and HPV 18 E6/E7 oncogene expression between in situ and invasive adenocarcinomas of the cervix uteri

Riethdorf

Milde‐Langosch

et al. 2000

Virchows Archiv

View full text Add to dashboard Cite

To evaluate the importance of high-risk human papillomavirus (HPV) types in in situ and invasive adeno- and adenosquamous carcinomas (ACISs/ACs, and ASCISs/ASCs) of the cervix uteri, we analyzed HPV infection and HPV 16- and HPV 18 E6/E7 oncogene expression in different histologic subtypes. Using the polymerase chain reaction (PCR) technique, 29 of 33 (88%) ACISs, 2 of 2 (100%) ASCISs, 46 of 54 (85%) ACs, and 8 of 10 (80%) ASCs were found to be HPV 16- and/or HPV 18-positive. In 25 of 35 (71%), 10 of 35 (29%), and 4 of 35 (11%) ACISs/ASCISs, HPV 16, HPV 18, and HPV 16 and HPV 18 were detected, respectively. Invasive ACs/ASCs were more frequently infected with HPV 18 (36 of 64, 56%) than with HPV 16 (28 of 64, 44%). Ten (16%) of these cases were positive for HPV 16 and HPV 18. In ACISs/ASCISs, HPV 16 oncogene expression predominated (62%) relative to HPV 18 (25%) expression, whereas in invasive ACs/ASCs, only 21% of the cases expressed HPV 16, but 48% of the cases expressed HPV 18 oncogenes. Thus, detection of HPV 18 in ACISs/ASCISs might be associated with an increased risk of progression. HPV oncogene expression was not dependent on histologic subtype of in situ or invasive AC. Normal glandular epithelia and glandular dysplasias (GDs, n = 4) were always negative concerning HPV oncogene expression. In HPV 16- and HPV 18-double-infected cases, HPV 18 oncogene expression was most frequently detected, and we did not find a coexpression of HPV 16- and HPV 18-specific oncogenes in purely glandular lesions or in cases with an additional CIN (cervical intraepithelial neoplasia) II or CIN III. HPV E6/E7 expression of the same HPV type in both in situ or invasive ACs and associated CIN II/III suggest that these lesions might be histogenetically related.

show abstract

“…These authors postulated that this glandular lesion was a precursor to invasive adenocarcinoma similar to preinvasive squamous cell carcinoma in situ. An increase in the incidence of cervical AIS has been reported in recent years [3][4][5]. In this fact may contributed an increased prevalence of HPV 18, the pathologist's awareness of the lesion and an increase in use of oral contraceptives.…”

Section: Cervical Adenocarcinoma In Situ (Ais)mentioning

confidence: 99%

Cervical Adenocarcinoma In situ Presentation of the Case and Review of Incidence, Recurrence Rate and Therapeutic Options

Zoi¹,

Paraskeui²

2015

Gynecol Obstet (Sunnyvale)

View full text Add to dashboard Cite

Cervical adenocarcinoma in situ (AIS) is a Adenocarcinoma in situ of the cervix (AIS) is a premalignant lesion that was first described by Helper in 1952 in his review of adenocarcinoma of the cervix.The following year Friedal reported two women who had undergone therapy for squamous cervical lesions and had concomitant cervical AIS.These authors postulated that this glandular lesion was a precursor to invasive adenocarcinoma similar to preinvasive squamous cell carcinoma in situ. An increase in the incidence of cervical AIS has been reported in recent years. In this fact may contributed an increased prevalence of HPV18, the pathologist's awareness of the lesion and an increase in use of oral contraceptives.

show abstract

The Histologic Diagnosis of Adenocarcinoma in Situ and Related Lesions of the Cervix Uteri

Cited by 18 publications

References 0 publications

Papanicolaou Smear Sensitivity for Adenocarcinoma In Situ of the Cervix:A Study of 34 Cases

Papanicolaou Smear Sensitivity for Adenocarcinoma In Situ of the Cervix:A Study of 34 Cases

Differences in HPV 16- and HPV 18 E6/E7 oncogene expression between in situ and invasive adenocarcinomas of the cervix uteri

Cervical Adenocarcinoma In situ Presentation of the Case and Review of Incidence, Recurrence Rate and Therapeutic Options

Contact Info

Product

Resources

About